Ampio enrolls patients in COVID-19 clinical trial

By The Science Advisory Board staff writers

July 23, 2020 -- Ampio Pharmaceuticals has begun patient enrollment for its previously announced COVID-19 phase I clinical trial to evaluate its Ampion drug candidate.

Ampion is based on an immunomodulatory molecule derived from the N-terminus of the human serum albumin. The trial will evaluate its intravenous application as a treatment for patients with COVID-19 who are on supplemental oxygen.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.